Charging Robotics

充电机器人

is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments where conventional cables and plug-in infrastructure cannot operate.

是全球少数几家开发创新无线充电系统的企业之一，这些系统专为自动化停车设施和自主移动平台设计，适用于传统电缆和插电式基础设施无法运行的环境。

Vancouver, Canada, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the 'Company'), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a definitive agreement (“Agreement”) to acquire a 51% stake in .

加拿大温哥华，2026年9月4日（环球电讯社）——Clearmind Medicine Inc.（纳斯达克股票代码：CMND）（以下简称“Clearmind”或“公司”），一家专注于发现和发展新型、非致幻性第二代致幻剂神经可塑性衍生疗法以解决主要治疗不足的健康问题的临床阶段生物科技公司，今日宣布已签订一项最终协议（“协议”），收购某公司51%的股权。

Charging Robotics

充电机器人

, an intelligent EV (electric vehicles) wireless charging solutions for automated parking systems and autonomous mobile platforms company (“Charging Robotics”).

，一家为自动泊车系统和自主移动平台提供智能电动汽车（EV）无线充电解决方案的公司（“Charging Robotics”）。

Charging Robotics

充电机器人

develops dedicated intelligent wireless charging systems designed specifically for automated parking facilities, autonomous mobile platforms, and robotaxi operations, environments where conventional cables and plug-in infrastructure cannot operate. Its proprietary technology delivers continuous charging of up to 10 kW, with smart vehicle communication and dynamic energy management that allocates power in real time.

开发专为自动化停车设施、自主移动平台和机器人出租车运营设计的专用智能无线充电系统，适用于传统电缆和插电式基础设施无法运作的环境。其专有技术提供高达10千瓦的连续充电能力，并具备智能车辆通信和动态能源管理功能，可实时分配电力。

The system integrates directly into robotic parking platforms and autonomous vehicle workflows, requiring no manual connection and no traditional charging stations. The technology is designed to make EV charging a background function of smart parking and autonomous mobility, improving utilization, safety, and the end-user experience in dense urban settings..

该系统直接集成到机器人停车平台和自动驾驶车辆工作流中，无需人工连接，也无需传统充电站。该技术旨在将电动汽车充电作为智能停车和自动移动出行的后台功能，从而提高密集城市环境中的利用率、安全性和终端用户体验。

Under the terms of the Agreement, Clearmind will acquire the majority stake of Charging Robotics for an aggregate purchase price of $2.5 million (the “Acquisition”). In addition, in connection with and as a condition to the closing of the Acquisition (the “Closing”), the Company shall extend a loan to Charging Robotics in the principal amount of $1.5 million (the “Loan”).

根据协议条款，Clearmind 将以 250 万美元的总收购价收购 Charging Robotics 的多数股权（以下简称“本次收购”）。此外，作为与本次收购交割（以下简称“交割”）相关且为交割的前提条件，公司应向 Charging Robotics 提供本金金额为 150 万美元的贷款（以下简称“该贷款”）。

The Loan shall bear interest at a rate of 4% per annum..

贷款应按年利率4%计息。

Unless earlier repaid, the outstanding principal amount of the Loan, together with accrued and unpaid interest, will become due and payable on the three-year anniversary of the Closing. If, as of that date, Charging Robotics has not generated positive cash flow from its operating and financing activities, together with available financing sources, sufficient to repay the outstanding loan amount, as reflected in its most recently completed financial statements prepared in accordance with IFRS, the repayment date will automatically be extended until the first date on which Charging Robotics has generated such cash flow and available financing sources.

除非提前偿还，贷款的未偿本金连同应计未付利息将在交割日三周年之日到期并应付。如果截至该日，Charging Robotics 根据其按照国际财务报告准则（IFRS）编制的最近一期已完成的财务报表所反映的情况，未能从其经营和融资活动中产生足以偿还贷款未偿金额的正面现金流，并结合可用的融资来源，则还款日期将自动延至 Charging Robotics 首次产生此类现金流及可用融资来源之日。

During any extension period, the outstanding principal amount will continue to accrue interest at the rate of 4.0% per annum..

在任何延期期间，未偿还本金将继续按每年4.0%的利率计息。

The Closing of the Acquisition is expected to occur during the week of September 7, 2026, subject to the satisfaction of certain closing conditions.

预计收购交割将于2026年9月7日当周进行，但须满足若干交割条件。

About Clearmind

关于 Clearmind

Medicine Inc.

医药公司

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements..

Clearmind 是一家处于临床阶段的神经可塑性药物生物技术公司，专注于发现和开发非致幻的第二代神经可塑性衍生疗法，以解决包括酒精使用障碍在内的广泛且未被充分满足的健康问题。其主要目标是研究和开发基于致幻剂的化合物，并尝试将其作为受监管的药品、食品或补充剂进行商业化。

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio..

公司的知识产权组合目前由19个专利家族组成，其中包括32项已授权专利。公司打算在必要时为其化合物申请更多专利，并将抓住机会收购额外的知识产权，以扩充其知识产权组合。

Shares of Clearmind are listed for trading on Nasdaq under the symbol 'CMND.'

Clearmind 的股票在纳斯达克上市交易，股票代码为“CMND”。

For further information, visit:

欲了解更多信息，请访问：

https://www.clearmindmedicine.com

https://www.clearmindmedicine.com

or contact:

或联系：

Investor Relations

投资者关系

invest@clearmindmedicine.com

invest@clearmindmedicine.com

www.Clearmindmedicine.com

www.Clearmindmedicine.com

Forward-Looking Statements:

前瞻性陈述：

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements.

本新闻稿包含《私人证券诉讼改革法案》及其他证券法律所定义的“前瞻性陈述”。诸如“预期”、“预计”、“打算”、“计划”、“相信”、“寻求”、“估计”等词语及类似表述或这些词语的变体，旨在识别前瞻性陈述。

For example, the Company is using forward-looking statements when it discusses the timing and completion of the acquisition and the satisfaction of closing conditions related to the acquisition. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain.

例如，当公司讨论收购的时间安排和完成情况以及与收购相关的交割条件的满足时，所使用的陈述属于前瞻性陈述。前瞻性陈述并非历史事实，而是基于管理层当前的预期、信念和预测，其中许多就其性质而言具有固有的不确定性。

Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements.

此类预期、信念和预测均基于诚信原则作出。然而，无法保证管理层的预期、信念和预测能够实现，实际结果可能与前瞻性陈述中表达或暗示的内容存在重大差异。前瞻性陈述受限于各种风险和不确定性，这些因素可能导致实际表现或结果与前瞻性陈述中表达的内容存在重大差异。

For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC.

有关影响本公司的风险及不确定性的更详细描述，请参阅本公司不时向美国证券交易委员会（“SEC”）提交的报告，包括但不限于本公司截至2025年10月31日财政年度的20-F表年度报告中详述的风险以及随后向SEC提交的文件。

Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or cir.

前瞻性陈述仅反映作出该等陈述之日的情况。本公司不承担更新前瞻性陈述以反映实际结果、后续事件或情况的义务。